Angelini Ventures
Angelini Ventures Co-Leads €105 Million Series A for Adcytherix to advance Next-Generation ADC Therapies
Angelini Ventures has co-led Adcytherix’s €105 million Series A financing round — the largest ADC-focused Series A in Europe in 2025 — alongside Bpifrance, Kurma Partners, and Andera Partners.
Adcytherix is a French biopharmaceutical company pioneering the development of novel antibody-drug conjugates (ADC) designed to treat cancers with high unmet medical needs.
The financing will enable the company to advance its lead candidate, ADCX-020, into clinical development, with first regulatory filings planned by the end of 2025. It will also support the expansion of Adcytherix’s proprietary ADC pipeline leveraging innovative payload technologies aimed at overcoming treatment resistance.
In a field were speed and in-depth knowledge is vital, Jack Elands and team stand out as experienced operators, that know the ADC world inside out. Their effectiveness in sourcing, profiling and developing product candidates for relevant patient groups is exceptional. We are very grateful to work with you all at ADCythrerix!
Regina Hodits,
With this investment, Angelini Ventures continues to back breakthrough science and transformative approaches that have the potential to redefine cancer therapy and improve patient outcomes worldwide.